DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

Phase 1

Completed

Conditions: Liver Disease
Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic
Leukemia, Myeloid, Acute
Renal Insufficiency
Neoplasms

Interventions: Drug: Azacitidine
Drug: Pevonedistat

First Posted Date: 2019-01-23

Last Posted Date: 2022-12-09

Lead Sponsor: Takeda

Target Recruit Count: 17

Registration Number: NCT03814005

Locations: 🇪🇸
ICO lHospitalet Hospital Duran i Reynals, LHospitalet de Llobregat, Barcelona, Spain
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

and more 5 locations

A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet

Phase 1

Completed

Conditions: Japanese Healthy Adult Male

Interventions: Drug: TAK-438 OD
Drug: TAK-438

First Posted Date: 2019-01-17

Last Posted Date: 2020-04-07

Lead Sponsor: Takeda

Target Recruit Count: 48

Registration Number: NCT03808493

Locations: 🇯🇵
Sekino Clinical Pharmacology Clininc, Toshima-ku, Tokyo, Japan

A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Mobocertinib

First Posted Date: 2019-01-17

Last Posted Date: 2025-05-15

Lead Sponsor: Takeda

Target Recruit Count: 53

Registration Number: NCT03807778

Locations: 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
Hokkaido Cancer Center, Sapporo, Hokkaido, Japan
🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan

and more 22 locations

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 60 mg dexlansoprazole capsules manufactured at TOB
Drug: 30 mg dexlansoprazole capsules manufactured at TOB
Drug: 30 mg dexlansoprazole capsules manufactured at TPC
Drug: 60 mg dexlansoprazole capsules manufactured at TPC

First Posted Date: 2019-01-11

Last Posted Date: 2020-03-19

Lead Sponsor: Takeda

Target Recruit Count: 122

Registration Number: NCT03801148

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults

Phase 3

Completed

Conditions: Dengue Fever

Interventions: Biological: Tetravalent Dengue Vaccine (TDV)

First Posted Date: 2018-12-11

Last Posted Date: 2021-06-07

Lead Sponsor: Takeda

Target Recruit Count: 200

Registration Number: NCT03771963

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Hutchinson Clinic, Hutchinson, Kansas, United States

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Niraparib

First Posted Date: 2018-11-30

Last Posted Date: 2024-06-07

Lead Sponsor: Takeda

Target Recruit Count: 19

Registration Number: NCT03759587

Locations: 🇯🇵
Hirosaki University Hospital, Hirosaki, Aomori, Japan
🇯🇵
Iwate Medical University Hospital, Morioka, Iwate, Japan
🇯🇵
Kurume University Hospital, Kurume, Fukuoka, Japan

and more 24 locations

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cancer

Interventions: Drug: Niraparib

First Posted Date: 2018-11-30

Last Posted Date: 2024-07-16

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT03759600

Locations: 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵
Hirosaki University Hospital, Hirosaki, Aomori, Japan
🇯🇵
Iwate Medical University Hospital, Morioka, Iwate, Japan

and more 30 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy

Phase 1

Completed

Conditions: Healthy Participants
Narcolepsy

Interventions: Drug: TAK-925
Drug: Placebo

First Posted Date: 2018-11-21

Last Posted Date: 2020-12-08

Lead Sponsor: Takeda

Target Recruit Count: 57

Registration Number: NCT03748979

Locations: 🇯🇵
PS Clinic, Fukuoka, Japan
🇯🇵
Sumida Hospital, Sumida-ku, Tokyo, Japan
🇯🇵
Hakata Clinic, Fukuoka, Japan

Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults

Phase 2

Completed

Conditions: Dengue Fever

Interventions: Biological: TDV

First Posted Date: 2018-11-19

Last Posted Date: 2025-01-13

Lead Sponsor: Takeda

Target Recruit Count: 30

Registration Number: NCT03746015

Locations: 🇺🇸
Optimal Research, Peoria, Illinois, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States

Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease

Phase 2

Completed

Conditions: Celiac Disease

Interventions: Drug: TIMP-GLIA
Drug: Placebo

First Posted Date: 2018-11-13

Last Posted Date: 2020-08-12

Lead Sponsor: Takeda

Target Recruit Count: 34

Registration Number: NCT03738475

Locations: 🇺🇸
Advanced Clinical Research, West Jordan, Utah, United States
🇺🇸
Prism Clinical Research, Saint Paul, Minnesota, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy